The approval based on the results of a global, double-blind, randomized phase 2/3 study (RELATIVITY-047), demonstrating the superiority in PFS of combined PD-1/LAG-3 inhibition with relatlimab plus nivolumab compared to nivolumab alone in patients with untreated metastatic or unresectable melanoma [8••]. Here, LAG3 is linked to melanoma.